Abstract:Abstract As part of the inflammatory response by macrophages, Irg1 is induced, resulting in millimolar quantities of itaconate being produced. This immunometabolite remodels the macrophage metabolome and acts as an antimicrobial agent when excreted. Itaconate is not synthesized within the erythron but instead may be acquired from central macrophages within the erythroid island. Previously, we reported that itaconate inhibits hemoglobinization of developing erythroid cells. Herein we show that this action is accomplished by inhibition of tetrapyrrole synthesis. In differentiating erythroid precursors, cellular heme and protoporphyrin IX synthesis are reduced by itaconate at an early step in the pathway. In addition, itaconate causes global alterations in cellular metabolite pools, resulting in elevated levels of succinate, 2-hydroxyglutarate, pyruvate, glyoxylate, and intermediates of glycolytic shunts. Itaconate taken up by the developing erythron can be converted to itaconyl–coenzyme A (CoA) by the enzyme succinyl-CoA:glutarate-CoA transferase. Propionyl-CoA, propionyl-carnitine, methylmalonic acid, heptadecanoic acid, and nonanoic acid, as well as the aliphatic amino acids threonine, valine, methionine, and isoleucine, are increased, likely due to the impact of endogenous itaconyl-CoA synthesis. We further show that itaconyl-CoA is a competitive inhibitor of the erythroid-specific 5-aminolevulinate synthase (ALAS2), the first and rate-limiting step in heme synthesis. These findings strongly support our hypothesis that the inhibition of heme synthesis observed in chronic inflammation is mediated not only by iron limitation but also by limitation of tetrapyrrole synthesis at the point of ALAS2 catalysis by itaconate. Thus, we propose that macrophage-derived itaconate promotes anemia during an inflammatory response in the erythroid compartment.

Itaconate promotes an unexpected tumor immune escape mechanism

Itaconate Uptake Via SLC13A3 Improves Hepatic Antibacterial Innate Immunity

The Emerging Application of Itaconate: Promising Molecular Targets and Therapeutic Opportunities.

The Cell Autonomous and Non-Autonomous Roles of Itaconate in Immune Response

Itaconate is a Lysosomal Inducer That Promotes Antibacterial Innate Immunity.

Cancer cell-intrinsic biosynthesis of itaconate promotes tumor immunogenicity

Itaconate Regulates Macrophage Function Through Stressful Iron-Sulfur Cluster Disrupting And Iron Metabolism Rebalancing

Itaconate promotes hepatocellular carcinoma progression by epigenetic induction of CD8+ T-cell exhaustion

The immunometabolite itaconate inhibits heme synthesis and remodels cellular metabolism in erythroid precursors

Metabolic Messengers: itaconate

Metabolite itaconate in host immunoregulation and defense

Itaconate: the poster child of metabolic reprogramming in macrophage function

Itaconate: A Metabolite Regulates Inflammation Response and Oxidative Stress

Tumor-associated macrophage-derived itaconic acid contributes to nasopharyngeal carcinoma progression by promoting immune escape via TET2

Itaconate in host inflammation and defense

Endogenously produced itaconate negatively regulates innate-driven cytokine production and drives global ubiquitination in human macrophages

Itaconate drives mtRNA-mediated type I interferon production through inhibition of succinate dehydrogenase

Itaconate as a potential target for antimalarial therapy

Itaconate modulates mitochondria for antiviral IFN-β

Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1

Tumor Immune Checkpoints and Their Associated Inhibitors